Multiple Trial Regimens Demonstrate Efficacy for RET-Mutated Medullary Thyroid CancerMarch 31st 2021
A number of clinical trials have provided evidence of efficacy of combination regimens for the treatment of RET-mutant medullary thyroid cancer. During a virtual Targeted Oncology Case-based Roundtable event, Lori Wirth, MD, discussed the options for a 58-year-old man with RET-mutant medullary thyroid cancer.
Ca19.9 Positivity Indicative of Mortality from Medullary Thyroid CancerMarch 15th 2021
In advanced medullary thyroid cancer, mortality may be predicted by serum carbohydrate antigen 19.9 (Ca19.9) positivity in patients as well as by doubling times less than 6 months and less than 1 year. Results of a retrospective study suggest that these 2 new prognostic factors should be considered when initiating treatment for patients with MTC.
A Decade of Thyroid Cancer Research Brings Precision Medicine to the Forefront of CareFebruary 26th 2021
The rising prevalence of thyroid cancer and thyroid nodules, especially for differentiated thyroid cancer, has brought into question the management of disease as it is known today.
Cabozantinib Lands Breakthrough Therapy Designation in RAI-Refractory Differentiated Thyroid CancerFebruary 26th 2021
The FDA has granted Breakthrough Therapy Designation to cabozantinib for the potential treatment of patients with differentiated thyroid cancer that has progressed following prior therapy and who are radioactive iodine-refractory if eligible for radioactive iodine.
Larotrectinib Excites Landscape for TRK Fusion-Positive Thyroid CancersJanuary 18th 2021
In an interview with Targeted Oncology, Maria E. Cabanillas, MD, discussed the use of larotrectinib as treatment of patients with thyroid cancer and the pooled findings from 2 larotrectinib trials.
Analysis Determines Potential Feasibility of PSMA PET Imaging for Metastatic Thyroid CancerJanuary 14th 2021
Gallium-68 prostate-specific membrane antigen PET imaging demonstrated the ability to detect metastatic thyroid cancer but resulted in a lower detection rate compared with 2-[18F]FDG PET for thyroid cancer lesion visualization.
Tissue TMB Shows Potential as Biomarker of Response to Pembrolizumab in Thyroid CancerJanuary 12th 2021
Patients with tissue tumor mutational burden-high solid tumors represent a subset of patients who could have a robust tumor response to the immune checkpoint inhibitor pembrolizumab as monotherapy, suggesting tTMB may be a novel and useful predictor of response in patients with previously treated recurrent or metastatic advanced solid tumors, including thyroid cancer.
VEGFR Targeting with Cabozantinib Achieves PFS Benefit in RAI-Refractory DTCDecember 22nd 2020
Cabozantinib demonstrated significant improvement in progression-free survival in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after up to 2 prior vascular endothelial growth factor receptor-targeted therapies compared with placebo, meeting the primary end point of the pivotal phase 3 COSMIC-311 clinical trial.
Sorafenib Assessed for Efficacy in the Real-World DTC SettingDecember 17th 2020
Marcia Brose, MD, PhD, discusses a global, non-interventional study that assessed the use of sorafenib as treatment of patients with asymptomatic radioiodine-refractory differentiated thyroid cancer.
Multiple Studies Provide Efficacy Results for Lenvatinib in Thyroid CancerNovember 27th 2020
Matthew Taylor, MD, reviewed the clinical trials supporting levantinib as a treatment option for a patient with thyroid cancer and discussed the option with a group of oncologists during a Targeted Oncology Case Base Peer Perspectives event.
Multikinase Inhibitor Options Abound for Patients With RET-Mutant Medullary Thyroid CancerNovember 25th 2020
During a Targeted Oncology Case Based Peer Perspectives event, Marcia S. Brose, MD, PhD, discussed options for a 58-year-old patient with RET-mutant medullary thyroid cancer.
Task Force Recommends Active Surveillance for Many Low-Risk Papillary Thyroid Microcarcinoma PatientsNovember 19th 2020
Active surveillance can be a safe and appropriate management strategy for patients with T1aN0M0 low-risk papillary thyroid microcarcinoma, though the decision to use the strategy requires multidisciplinary teams and patient input, according to a new report.
Real-World Date Confirm Vandetanib and Cabozantinib Are Effective 1L/2L Treatments for Medullary Thyroid CancerNovember 19th 2020
For the majority of patients with medullary thyroid cancer, vandetanib and cabozantinib are both effective treatment options, according to results from a retrospective analysis.
Real-World Data Support Use of Multikinase Inhibitors in Differentiated Thyroid CancerOctober 20th 2020
In an interview with Targeted Oncology, Marcia Brose, MD, PhD, discussed the findings for the global, non-interventional study that assessed the use of sorafenib as treatment of patients with asymptomatic radioiodine-refractory differentiated thyroid cancer.